<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>HOTH THERAPEUTICS 1 RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Wed, 29 Apr 2026 19:38:00 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/hoth%5Ftherapeutics%5F1%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>HOTH THERAPEUTICS 1 RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>Hoth Therapeutics stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor</title><pubDate>Sun, 29 Mar 2026 06:35:06 +0200</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-stellte-quartalsergebnis-zum-abgelaufenen-jahresviertel-vor-15582836</link><description><![CDATA[<p><a href="https://www.finanzen.net/aktien/hoth_therapeutics_1-aktie">Hoth Therapeutics</a> hat am 27.03.2026 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 31.12.2025 – vorgestellt.Dabei wurde ein Verlust je Aktie von 0,16 USD ausgewiesen. ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-stellte-quartalsergebnis-zum-abgelaufenen-jahresviertel-vor-15582836</guid></item><item><title>Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform</title><pubDate>Fri, 02 Jan 2026 14:13:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-15389188</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">NEW YORK, <span class="legendSpanClass"><span class="xn-chron">Jan. 2, 2026 /PRNewswire/ -- <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4588140-1&h=1324831692&u=http%3A%2F%2Fwww.hoththerapeutics.com%2F&a=Hoth+Therapeutics"  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-15389188</guid></item><item><title>Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program</title><pubDate>Wed, 03 Dec 2025 20:00:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-issues-comprehensive-pipeline-update-highlighting-clinical-progress-orphan-designated-ht-kit-advancing-ht-001-phase-2-and-new-gdnf-metabolic-program-15333352</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">NEW YORK, <span class="legendSpanClass"><span class="xn-chron">Dec. 3, 2025 /PRNewswire/ -- <b>Hoth Therapeutics, Inc. (NASDAQ: HOTH)</b>, a patient-focused  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-issues-comprehensive-pipeline-update-highlighting-clinical-progress-orphan-designated-ht-kit-advancing-ht-001-phase-2-and-new-gdnf-metabolic-program-15333352</guid></item><item><title>Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025</title><pubDate>Mon, 01 Dec 2025 14:03:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference-december-2-3-2025-15324866</link><description><![CDATA[<p><p class="prntac" xmlns="http://www.w3.org/1999/xhtml"><i>NobleCon is the preeminent showcase of small and microcap companies</i><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">NEW YORK, <span class="legendSpanClass"><span  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference-december-2-3-2025-15324866</guid></item><item><title>Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities</title><pubDate>Thu, 20 Nov 2025 14:13:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-accepted-into-nvidia-connect-program-expanding-its-ai-and-accelerated-computing-capabilities-15295415</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">NEW YORK, <span class="legendSpanClass"><span class="xn-chron">Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-accepted-into-nvidia-connect-program-expanding-its-ai-and-accelerated-computing-capabilities-15295415</guid></item><item><title>Hoth Therapeutics stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor</title><pubDate>Sat, 15 Nov 2025 06:35:06 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-stellte-quartalsergebnis-zum-abgelaufenen-jahresviertel-vor-15279202</link><description><![CDATA[<p><a href="https://www.finanzen.net/aktien/hoth_therapeutics_1-aktie">Hoth Therapeutics</a> hat in der Finanzkonferenz zum Quartalsende am 12.11.2025 die Bücher zum vergangenen Jahresviertel geöffnet, das am 30.09.2025 abgelaufen war.Dabei wurde ein Verlust je Aktie von 0,30 USD  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/hoth-therapeutics-stellte-quartalsergebnis-zum-abgelaufenen-jahresviertel-vor-15279202</guid></item></channel></rss>
